China Competitors Gain Shares From GSK As Anti-Graft Probe Continues
This article was originally published in PharmAsia News
Domestic competitors are the main gainers from reported sales declines of some GlaxoSmithKline products in China following anti-graft investigations that began in July, according to a report.
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.